The Clinical Efficacy of Epoetin Alfa and Darbepoetin Alfa in Patients with Low-Risk or Intermediate-1-Risk Myelodysplastic Syndrome: Retrospective Multi-center Real-Life Study

dc.date.accessioned	2023-03-06T07:32:51Z
dc.date.available	2023-03-06T07:32:51Z
dc.date.issued	2022
dc.identifier.citation	Indian J Hematol Blood Transfus. 2022 Apr;38(2):299-308. doi: 10.1007/s12288-021-01458-1. Epub 2021 Jun 26.
dc.identifier.uri	https://hdl.handle.net/20.500.12619/100461
dc.relation.isversionof	10.1007/s12288-021-01458-1
dc.relation.isversionof	10.1007/s12288-021-01458-1
dc.title	The Clinical Efficacy of Epoetin Alfa and Darbepoetin Alfa in Patients with Low-Risk or Intermediate-1-Risk Myelodysplastic Syndrome: Retrospective Multi-center Real-Life Study
dc.relation.journal	Indian J Hematol Blood Transfus
dc.identifier.doi	10.1007/s12288-021-01458-1
dc.contributor.author	Ak MA
dc.contributor.author	Ak MA
dc.contributor.author	Sahip B
dc.contributor.author	Geduk A
dc.contributor.author	Ucar MA
dc.contributor.author	Kale H
dc.contributor.author	Hacibekiroglu T
dc.contributor.author	Polat MG